Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX
Eloxx Pharmaceuticals — Cantor Global Healthcare Conference 2018
28 slides from Eloxx Pharmaceuticals's conference presentation, Oct 2, 2018
Slide 1: Unlocking protein production with translational read-through for rare genetic diseases
Unlocking protein production with translational read-through for rare genetic diseases Cantor Global Healthcare, October 2, 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and simi
Slide 3: Eloxx Pharmaceutical Highlights
Eloxx Pharmaceutical Highlights 3
Slide 4: Built a Highly Experienced Leadership Team
Built a Highly Experienced Leadership Team Robert Ward Greg Williams, PhD David Snow CHAIRMAN AND CEO COO CBO Greg Weaver Neil Belloff, Esq. CFO GENERAL COUNSEL John van Duzer, PhD Neal Sharpe, PhD Barbara Ryan VP CMC VP TRANSLATIONAL SCIENCE INVESTOR RELATIONS 4
Slide 5: The Potential for Read-Through of Rare Genetic Diseases
The Potential for Read-Through of Rare Genetic Diseases Aminoglycosides' tolerability profile historically limited suitability for read-through Cystic Cystinosis Fibrosis treatment of serious genetic diseases >1,800 Aminoglycosides first Genetic showed read-through activity diseases MPS I Rett Duche
Slide 6: Targeting Read-Through Development Activities
Targeting Read-Through Development Activities Eloxx read-through program is pursuing product candidates with the following characteristics: Activity independent of gene size or Molecular scaffold Active at all three complexity of genetic disorder with defined premature stop ribosomal effect codons R
Slide 7: Defined Ribosomal Binding Site
Defined Ribosomal Binding Site • Well defined molecular interaction with helix 44 • Role in stabilization of tRNA binding at Site A • Optimizing scaffold by altering interaction with prokaryotic and mitochondrial ribosomes • Defined tissue penetration and tolerability profile for read-through applic
Slide 8: Discovery of the Eloxx Novel Compound Library
Discovery of the Eloxx Novel Compound Library • Novel compounds derived from aminoglycoside scaffold • Screened for read-through activity on known disease related nonsense mutations • Reduced mitochondrial inhibition (range 12-140X) • Reduced prokaryotic ribosomal inhibition Increased Selectivity to
Slide 9: Substantial Advantages for Orphan Drug Development
Substantial Advantages for Orphan Drug Development • ELOXX Focus on High Unmet Medical Need – Nonsense mutations represent important patient segments in over 1,800 diseases – Many of these diseases have no approved therapeutics – In some diseases the nonsense patient population is appropriate size f
Slide 10: Cystic Fibrosis Nonsense Mutation Patients Represent a Key Unmet Need Population
Cystic Fibrosis Nonsense Mutation Patients Represent a Key Unmet Need Population No Currently Approved Drugs Global Cystic Fibrosis Patients by To Treat CFTR Nonsense Mutations mutation/genotype CFTR Nonsense mutation subtypes Other Mutations R553X R1162X F508del Nonsense Mutations W1282X Related Mu
Slide 11: Organoids Pre-clinical Patient Stratification
Organoids Pre-clinical Patient Stratification Potential Use To Define Clinical Trial Populations A CF swelling assay on cystic fibrosis patient organoids Patient Organoid without drug treatment: Patient Organoid with drug treatment: No Swelling of Organoids Swelling of Organoids 11
Slide 12: Homozygous Nonsense Mutation (G542X) Organoid Response
Homozygous Nonsense Mutation (G542X) G542X Cystic Fibrosis Organoid Homozygous Responsive to ELX-02, Enhanced by Combination 200 ELX-02 + Potentiator & Corrector 180 Organoids Swelling (Normalised Area) ELX-02* 160 140 120 Potentiator & Corrector 100 0 20 40 60 80 100 120 Timepoint (min) • As presen
Slide 13: Complex Heterozygous Nonsense Mutation (G542X:R1066C)
Complex Heterozygous Nonsense Mutation (G542X:R1066C missense) Cystic Fibrosis Organoid Responsive to ELX-02, Enhanced by Combination G542X Complex Heterozygote (R1066C) 200 ELX-02 + Potentiator & Corrector 180 Organoids Swelling (Normalised Area) ELX-02* 160 140 120 Potentiator & Corrector 100 0 20
Slide 14: Complex Heterozygous Nonsense Mutation (R1162X:F508del)
Complex Heterozygous Nonsense Mutation (R1162X nonsense:F508del) CysticCompound R1162X Fibrosis Organoid Responsive Heterozygote to ELX-02 (F508del) 160 ELX-02* Organoids Swelling (Normalised Area) 140 Potentiator & Corrector 120 Potentiator 100 0 20 40 60 80 100 120 Timepoint (min) • As presented a
Slide 15: Complex Heterozygous Nonsense Mutation (G542X:F508del)
Complex Heterozygous Nonsense Mutation (G542X:F508del) Cystic Fibrosis Organoid Responsive to ELX-02, Enhanced by Combination G542X complex heterozygote (F508del) 200 ELX-02 + Potentiator & Corrector 180 Potentiator & Corrector Organoids Swelling (Normalised Area) 160 ELX-02* 140 120 100 0 20 40 60
Slide 16: Homozygous Deletion Mutation (F508del) Not Responsive
Homozygous Deletion Mutation (F508del) Cystic Fibrosis Organoids Without Nonsense Mutations areF508del Homozygous Not Responsive to ELX-02 200 190 180 Organoids Swelling 170 (Normalised Area) 160 150 140 130 120 110 ELX-02* 100 90 0 20 40 60 80 100 120 Timepoint (min) • As presented at the European
Slide 17: ELX-02 Clinical Development – Phase 1 Studies
ELX-02 Clinical Development – Phase 1 Studies CLINICALTRIALS.GOV CLINICALTRIALS.GOV Identifier: NCT03292302 Identifier: NCT03309605 A Phase 1a, Randomized, Double-blinded, A Phase 1, Randomized, Placebo-Controlled, Single Dose Escalation Double-Blinded, Placebo-Controlled, Third Study to Evaluate th
Slide 18: Clinical Update for ELX-02 Phase 2 in Cystic Fibrosis
Clinical Update for ELX-02 Phase 2 in Cystic Fibrosis √ Submitted Orphan Drug Application to EMA √ Clinical Trial Application (CTA) for Phase 2 Study received final approved by the FAMHP in Belgium • Expanding MAD Study √ 4th Cohort Completed • Additional Cohorts to Evaluate Drug Concentrations • En
Slide 19: Eloxx Presentation at ATA, October 18-20, 2018
October 18-20, 2018 · Denver, CO ATA Eloxx Presentation D NEW “Measuring mRNA Levels in Cystic Fibrosis Organoids with Nonsense Mutations Following Treatment with ELX-02” October 18 19
Slide 20: Clinical Update for ELX-02 Phase 2 in Cystinosis
Clinical Update for ELX-02 Phase 2 in Cystinosis √ FDA granted ELX-02 orphan drug status in cystinosis √ IND for ELX-02 in cystinosis is open in the US • Engaging Investigators on Phase 2 protocol • Will evaluate changes in cysteine levels in white blood cells • Study will be posted on clintrials.go
Slide 21: On Track for Advancing Pipeline in 2018
On Track for Advancing Pipeline in 2018 Multiple Novel Compounds Are Advancing To IND Enabling Studies Eloxx holds global rights on these library compounds Extensive Intellectual ELX-02 Composition of Matter 2031 without extensions Property Portfolio Library Composition of Matter from 2027-2038 or l
Slide 22: Novel Compound Library has Demonstrated Activity across Multiple Orphan Diseases
Novel Compound Library has Demonstrated Activity across Multiple Orphan Diseases 22
Slide 23: Substantial Potential Ocular Orphan Opportunity
Substantial Potential Ocular Orphan Opportunity Population values from National Organization for Rare Disorders (NORD) Han et al, Korean J Pediatr 2016.; Wilkin et al, Am J Med Genet 2000; Freund et al, Mol Genet Genomic Med 2016; Aparisi et al, Orphan J Rare Dis 2014 23
Slide 24: Usher Syndrome
Usher Syndrome • No drugs approved or in late-stage development for nonsense variants • Significant unmet medical need for nonsense forms • Over 4,000 patients in North America alone • Academic collaborations have demonstrated activity with Eloxx Novel Library Compounds • Read through • Protein expr
Slide 25: In Vitro Retinal Biocompatibility
In Vitro Retinal Biocompatibility • Studies in retinal culture have demonstrated distinct biocompatibility profile, ie, no change in retinal staining or structure1 • Multiple Library Compounds2 have been evaluated to date • Additional supportive preclinical studies ongoing 1Goldmann et al. EMBO Mol
Slide 26: Demonstration of Usher Protein Production
Demonstration of Usher Protein Production Goldmann et al. EMBO Mol Med 2012, 4(11):1186-1199 • Collaborations with the Ben-Yosef and Nagel-Wolfrum labs demonstrate potential: ü Favorable safety profile in the retina ü Readthrough of relevant eye-disorder mutations ü Production of missing protein 26
Slide 27: Eloxx Pharmaceutical Highlights
Eloxx Pharmaceutical Highlights 27
Slide 28: Thank you.
Thank you. Cantor Global Healthcare, October 2, 2018
Eloxx Pharmaceuticals — Cantor Global Healthcare Conference 2018 on 6ix